Rigel Pharmaceuticals, Inc.
448 articles about Rigel Pharmaceuticals, Inc.
-
Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update
8/1/2023
Rigel Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
7/25/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close on Tuesday, August 1, 2023.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - July 05, 2023
7/5/2023
Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
-
Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
6/7/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced promising data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1)1, in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory (R/R) to prior venetoclax-based regimens.
-
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
6/6/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an expert review article in Blood Advances examining the development path and positioning of REZLIDHIA® (olutasidenib).
-
Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
6/1/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 2-6, 2023, in Chicago, IL , and virtually.
-
Rigel to Present at the Jefferies 2023 Global Healthcare Conference
5/31/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, will present on Wednesday, June 7, 2023 at 2:30 p.m. ET at the Jefferies 2023 Global Healthcare Conference, being held June 7-9, 2023 in New York, NY.
-
Rigel Reports First Quarter 2023 Financial Results and Provides Business Update
5/2/2023
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment and sales of REZLIDHIA® capsules for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
4/25/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close on Tuesday, May 2, 2023.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - April 06, 2023
4/6/2023
Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees' entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.
-
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/7/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
2/28/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.
-
Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
2/2/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication of data in Blood Advances, which summarizes clinical results from the Phase 2 registrational study of REZLIDHIA™ (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1)1, in patients with mIDH1 relapsed or refractory acute myeloid leukemia (R/R AML).
-
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
1/18/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA™ (olutasidenib) has been added by the National Comprehensive Cancer Network® (NCCN®) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for acute myeloid leukemia (AML).
-
Rigel Pharmaceuticals Provides Business Update - January 9, 2023
1/9/2023
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter, ongoing activity from the commercial portfolio, including TAVALISSE® (fostamatinib disodium hexahydrate) tablets and REZLIDHIA™ (olutasidenib) capsules, and upcoming catalysts for 2023.
-
Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
12/22/2022
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
-
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
12/15/2022
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it dosed the first patient in its Phase 1b study of R289, an IRAK1/4 dual inhibitor, in patients with lower-risk myelodysplastic syndromes (MDS) who are refractory or resistant to prior therapies.
-
Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients
12/13/2022
Optime Care, a member of the AscellaHealth Family of Companies, announced a contractual partnership with Rigel Pharmaceuticals, Inc., bringing its full suite patient support/HUB service capabilities to support Rezlidhia™, a recent FDA-approved treatment for adult patients with relapse or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test.
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - December 9, 2022
12/9/2022
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to an employee's entering into employment.
-
The FDA has approved Rigel's Rezlidhia for the treatment of adults with relapsed or refractory AML with a susceptible isocitrate dehydrogenase-1 mutation.